Phase 1 single-arm, open-label, multicenter trial to evaluate ovarian suppression following subcutaneous ZOLADEX10.8 mg in premenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer

16858TER-ZLDX-0101-MWHC-NCT07310420OpenPhase 1 single-arm, open-label, multicenter trial to evaluate ovarian suppression following subcutaneous ZOLADEX10.8 mg in premenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancerTER-ZLDX-0101NCT07310420IndustrialAdultTreatmentIGlobalBreastChitalia, AmiMedStar Health and GUMC; Medstar Washington Hospital Center : Stacy MalloyBreastOncology GroupMHRI Washington Cancer Institute10787Stacy MalloyStacy MalloyStacy.K.Malloy@medstar.net2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>